Guidance for evidence-informed policies about health systems: linking guidance development to policy developmentGuidance for evidence-informed policies about health systems: rationale for and challenges of guidance developmentOpen source drug discovery in practice: a case studyGuidance for evidence-informed policies about health systems: assessing how much confidence to place in the research evidenceAssessing implementation mechanisms for an international agreement on research and development for health productsSplit WHO in two: strengthening political decision-making and securing independent scientific adviceFinancing and collaboration on research and development for nodding syndromeThe need for global R&D coordination for infectious diseases with epidemic potential.Advancing the field of health systems research synthesisEfficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)Wiring a nation: putting knowledge into actionTreatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004An open source business model for malariaCEPI—a new global R&D organisation for epidemic preparedness and responseNew Vaccines against Epidemic Infectious DiseasesA framework convention on obesity control?Towards a coherent global framework for health financing: recommendations and recent developments.What level of domestic government health expenditure should we aspire to for universal health coverage?Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.Conceptual and institutional gaps: understanding how the WHO can become a more effective cross-sectoral collaboratorMapping of available health research and development data: what's there, what's missing, and what role is there for a global observatory?Using European travellers as an early alert to detect emerging pathogens in countries with limited laboratory resources.Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in UgandaTrends in health policy and systems research over the past decade: still too little capacity in low-income countriesA new deal for global health R&D? The recommendations of the Consultative Expert Working Group on Research and Development (CEWG).Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.Pharyngeal carriage of Neisseria meningitidis in 2-19-year-old individuals in Uganda.Are the Norwegian health research investments in line with the disease burden?Projected treatment capacity needs in sierra leone.Common characteristics of open source software development and applicability for drug discovery: a systematic review.Global trends in health research and development expenditures--the challenge of making reliable estimates for international comparison.A global biomedical R&D fund and mechanism for innovations of public health importance.Securing the public good of health research and development for developing countries.Metaanalysis and metaregression in interpreting study variability in the impact of sexually transmitted diseases on susceptibility to HIV infection.Strategies for achieving global collective action on antimicrobial resistance.International law's effects on health and its social determinants: protocol for a systematic review, meta-analysis, and meta-regression analysis.The impact of an intervention programme employing a hands-on technique to reduce the incidence of anal sphincter tears: interrupted time-series reanalysis.Developing Health Technology Assessment to address health care system needs.Practical tools and methods for health technology assessment in Europe: structures, methodologies, and tools developed by the European Network for Health Technology Assessment, EUnetHTA.An antibiotic's journey from marketing authorization to use, Norway.
P50
Q21092317-FD332784-FE10-4E32-AD72-3646E07FA424Q21092319-2DABACB4-1434-473D-B8F2-4F2CC036857CQ21144491-65D07838-48E0-4725-9D01-258CC9604D85Q21563020-98508890-2312-43CE-B8A4-BDAA2A515390Q22241277-903B7C56-3359-453B-898C-099BD5303741Q22251190-AC1E5A12-A5F8-458F-AB9F-251CF1A95AAAQ24288870-0134931A-316F-4D43-8514-D38EE96A6D68Q26250280-1B5DDBA9-D444-4C71-81FA-DE91E13D60AEQ26998703-F6232F35-446B-4892-AAA6-EC6CECD7DC71Q28051937-ADFF75E8-3F70-4D86-BE72-3C0EE64E7C0BQ28051937-B13F6C25-E85A-4831-B2D4-0F8D2E353E2FQ28277162-90218380-8984-494F-8723-75E21D18456FQ28283745-89908B8C-8FD4-4A57-AB4F-2FC72036B0F5Q28543356-A92171C4-263C-40FD-A384-30F40D24BA86Q28595117-18763B08-63EC-4EF6-9546-230B61DAC519Q28595117-C918EED3-9D96-4230-BD78-1B27CEC27AACQ28595135-9A210A85-44B2-43FC-A5B4-146FB5EDD5A9Q29014535-01575198-575E-4E86-AFA6-69AF5C852106Q30061772-E5D342DD-55FE-4B00-996F-99694FCB7E4FQ30061774-871BBEA8-F77F-412E-9331-221E8E788586Q30151817-A4BA75F1-975E-4D56-9CA9-D14AD885D022Q30386831-A031DA51-8E6A-4C80-9DE8-188770C061C6Q30630842-754E65D5-0AEB-4233-805D-F7F80E83524BQ33269861-4A9F63EF-E07B-46E1-AFC8-D2283DEA05B1Q33388680-FAC34E10-AB81-4F5D-902D-0C36B094970BQ34087694-4E941F4C-04D8-41D4-AF37-79D9FF674FC5Q34276950-0D99A9ED-795C-46A6-B8EC-F2E5FB47D416Q34488529-CBFF1B6B-A1BD-4C32-9365-6123849B71FEQ34536636-BE59DFC2-9722-4392-937B-B5C1302B0EAAQ34636332-2807CF38-EAF4-4758-8D40-768F2031B783Q35055377-A2222252-F749-4D26-BFC0-0F68E72E8048Q35505170-5EE9B8ED-1EDD-4DD6-86D9-AF6C616C7A7EQ35562188-36BC12E6-7C9C-4C40-BB65-24D91F29C6CEQ35592601-E7307A53-BACB-41D2-91A4-8728B9D54360Q35926636-31C4ECF0-A3C0-4A51-AF2A-8F2DF5AD80FBQ36136613-79F393CE-08AC-4DA3-BF30-B5C95C3D8AACQ36347030-12F0EB59-AA42-44D3-9A22-9BDD845EEC8AQ36804559-94A9A0E3-E9F7-4049-A05A-4800367F93D5Q37256393-8ADC10F8-537E-4E67-BD76-CDFD218B2183Q37627392-523EB576-45A6-4AA6-85A4-270756AAAA20
P50
description
Noors arts
@nl
Norra arst
@et
Norwegian physician
@en
Norwegian physician
@en-ca
Norwegian physician
@en-gb
dochtúir Ioruach
@ga
dokter asal Norwegia
@id
medic norvegian
@ro
metge noruec
@ca
mjek norvegjez
@sq
name
John-Arne Røttingen
@ast
John-Arne Røttingen
@ca
John-Arne Røttingen
@da
John-Arne Røttingen
@de
John-Arne Røttingen
@en
John-Arne Røttingen
@es
John-Arne Røttingen
@fo
John-Arne Røttingen
@fr
John-Arne Røttingen
@ga
John-Arne Røttingen
@is
type
label
John-Arne Røttingen
@ast
John-Arne Røttingen
@ca
John-Arne Røttingen
@da
John-Arne Røttingen
@de
John-Arne Røttingen
@en
John-Arne Røttingen
@es
John-Arne Røttingen
@fo
John-Arne Røttingen
@fr
John-Arne Røttingen
@ga
John-Arne Røttingen
@is
altLabel
John-Arne Rottingen
@nl
prefLabel
John-Arne Røttingen
@ast
John-Arne Røttingen
@ca
John-Arne Røttingen
@da
John-Arne Røttingen
@de
John-Arne Røttingen
@en
John-Arne Røttingen
@es
John-Arne Røttingen
@fo
John-Arne Røttingen
@fr
John-Arne Røttingen
@ga
John-Arne Røttingen
@is
P1015
P214
P244
P1015
P106
P19
P2002
jarottingen
P21
P214
P2287
P244
nb2015003223
P27
P31
P496
0000-0002-5587-4296
P512
P569
1969-03-27T00:00:00Z
P734
P7859
lccn-nb2015003223